Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Walnut Creek, California


Purpose:

Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of Exenatide LAR administered weekly by subcutaneous injection in people with type 2 diabetes mellitus.


Criteria:

Inclusion Criteria: - Has type 2 diabetes treated with either: *A stable regimen of metformin for a minimum of 3 months, and/or *Diet modification and exercise for a minimum of 3 months. - Has HbA1c of 7.1% to 11.0%, inclusive. - Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive. Exclusion Criteria: - Received any investigational drug within 3 months prior to screening. - Is currently treated with any of the following excluded medications: *Thiazolidinediones within 3 months of screening; * Sulfonylureas within 3 months of screening; * Insulin within 1 year of screening. - Participated previously in an exenatide clinical study.


NCT ID:

NCT00103935


Primary Contact:

Study Director
Lisa Porter, MD
Amylin Pharmaceuticals, LLC.


Backup Contact:

N/A


Location Contact:

Walnut Creek, California
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.